Compumedics Limited (ASX:CMP) has appointed Mr Syed Husain, Managing Partner of Red Brook Advisors, as strategic adviser to lead its Somfit® US pharmacy and consumer program, the company disclosed on 6 November 2026.
Key Points
- Syed Husain appointed as strategic adviser for the Somfit® US pharmacy and consumer program
- Husain is Managing Partner of Red Brook Advisors and a former Head of Corporate Development and M&A at a Fortune 5 US healthcare company
- The program is evaluating partnership, licensing, distribution and strategic investment opportunities for Somfit® and the NEXUS 360® platform
- The Board expects to make two to three further strategic investment or investment banking appointments by the end of the March 2027 quarter
Details of the Somfit® US Pharmacy and Consumer Program
The Somfit® US pharmacy and consumer program is evaluating partnership, licensing, distribution and strategic investment opportunities for the Somfit® product and the NEXUS 360® platform with US pharmacy, consumer-health and related healthcare groups. According to the filing, this appointment is the first of the Board's dedicated deal-maker appointments across its five value-realisation programs. The company stated that this approach is designed to realise value for shareholders through partnerships or strategic investment rather than by issuing new shares.
Background and Credentials of Syed Husain
Mr Husain is a registered pharmacist and healthcare mergers and acquisitions executive with more than 30 years' experience. Over almost 20 years at a Fortune 5 US healthcare company, he rose to the position of Head of Corporate Development and M&A. He subsequently founded the healthcare and pharmacy practice at a boutique Wall Street investment bank. Mr Husain has led Red Brook Advisors since 2023, according to the filing.
Further Strategic Appointments Planned by March 2027 Quarter
The filing states that the Board expects to make two to three further strategic investment or investment banking appointments by the end of the March 2027 quarter. The Husain appointment represents the first in a series of dedicated deal-maker roles across the company's five value-realisation programs. Compumedics is a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring applications, with subsidiaries in the United States and Germany.



Please wait processing your request...